
    
      This trial will evaluate the safety and efficacy of Camrelizumab plus Apatinib in
      participants with advanced non-squamous NSCLC previously treated with first-line
      immunotherapy. The primary objective of this pilot study is to determine the Camrelizumab
      plus Apatinib improves progression-free survival (PFS) . All the efficacy and safety are
      assessed by investigator : 1) response rate (ORR), 2) duration of response(DoR), 3) overall
      survival(OS), 4) disease control rate (DCR); the safety and quality of life assessment
      Explore objective is potential biomarker associated with efficacy.
    
  